NAM
LJPC

Nexpoint Asset Management’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Nexpoint Asset Management’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-49,000
Closed -$431K – 398
2019
Q3 		$431K Buy
+49,000
New +$463K 0.03% 263

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nexpoint Asset Management's LJPC Position: Q4 2019 in Review

Nexpoint Asset Management sold out of La Jolla Pharmaceutical Company (LJPC) in Q4 2019, closing a stake of 49,000 shares — an estimated $431K sold.

Nexpoint Asset Management first reported a position in LJPC in Q3 2019 and held it in 1 quarter. The position peaked at $431K in Q3 2019. 77 funds tracked by Wall St. Rank hold LJPC as of Q4 2019.

  • Nexpoint Asset Management reported no remaining La Jolla Pharmaceutical Company position as of Q4 2019 after selling out during the quarter.
  • Nexpoint Asset Management sold 49,000 La Jolla Pharmaceutical Company shares in Q4 2019, an estimated $431K.
  • Nexpoint Asset Management first reported a position in La Jolla Pharmaceutical Company in Q3 2019 and held it in 1 quarter.
  • Nexpoint Asset Management's La Jolla Pharmaceutical Company position peaked at $431K in Q3 2019.
  • 77 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q4 2019.

Based on Nexpoint Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.